Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5 - sprookjes - yvandenbroek - TriplyDB

Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5

Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5

http://www.wikidata.org/entity/Q27473038

about

Improved COBAS TaqMan Hepatitis C Virus Test (Version 2.0) for Use with the High Pure System: Enhanced Genotype Inclusivity and Performance Characteristics in a Multisite Study Multicenter Evaluation of the New Abbott RealTime Assays for Quantitative Detection of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus RNA Comparison of Performance Characteristics of Three Real-Time Reverse Transcription-PCR Test Systems for Detection and Quantification of Hepatitis C Virus Impact of Hepatitis C Virus (HCV) Genotypes on Quantification of HCV RNA in Serum by COBAS AmpliPrep/COBAS TaqMan HCV Test, Abbott Antiretroviral Therapy HCV RealTime Assay, and VERSANT HCV RNA Assay Multicenter Trials Need To Use the Same Assay for Hepatitis C Virus Viral Load Determination Performance Characteristics of a Quantitative Hepatitis C Virus RNA Assay Using COBAS AmpliPrep Total Nucleic Acid Isolation and COBAS TaqMan Hepatitis C Virus Analyte-Specific Reagent Differences between Two Real-Time PCR-Based Hepatitis C Virus (HCV) Assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and One Signal Amplification Assay (Versant HCV RNA 3.0) for RNA Detection and Quantification Clinical Performance Evaluation of Four Automated Chemiluminescence Immunoassays for Hepatitis C Virus Antibody Detection A Novel Diagnostic Target in the Hepatitis C Virus Genome Evaluation of the Abbott Investigational Use Only RealTime Hepatitis C Virus (HCV) Assay and Comparison to the Roche TaqMan HCV Analyte-Specific Reagent Assay Hepatitis C Virus RNA Quantitation in Venous and Capillary Small-Volume Whole-Blood Samples Expert opinion on the treatment of patients with chronic hepatitis C Prevalence of Diabetes Type 2 in Hepatitis C Infected Patients in Kpk, Pakistan A novel duplex real-time reverse transcriptase-polymerase chain reaction assay for the detection of hepatitis C viral RNA with armored RNA as internal control.HCV infection among Saudi population: high prevalence of genotype 4 and increased viral clearance rate Correlation of viral loads with HCV genotypes: higher levels of virus were revealed among blood donors infected with 6a strains.Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity.Direct quantitative analysis of HCV RNA by atomic force microscopy without labeling or amplification.Diagnosis and Management of Hepatitis C Virus Infection.Differences between quantification of genotype 3 hepatitis C virus RNA by Versions 1.0 and 2.0 of the COBAS AmpliPrep/COBAS TaqMan HCV Test.The COBAS ® TaqMan ® hepatitis C virus assays: automated systems for accurate and sensitive viral load quantification.Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection.Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response Genotype 3 diversity and quantification of hepatitis E virus RNA.Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors.Comparison of two quantitative real-time CMV-PCR tests calibrated against the 1st WHO international standard for viral load monitoring of renal transplant patients.Performance characteristics of a real-time RT-PCR assay for quantification of hepatitis C virus RNA in patients with genotype 1 and 2 infections.Detection of hepatitis C virus by an improved loop-mediated isothermal amplification assay.

P2860

Q24289102-AF9CFDF4-0430-45BD-A00F-5657DD7F95D3 Q27480924-14B1F226-7A40-46CE-8789-0E07221E898C Q27481004-B5581929-009E-43FD-B65A-92995D1AFF45 Q27481443-5AD55ACF-CB45-4FDE-87B9-4E63D8D553D8 Q27484906-D68F9E68-E77F-4492-A11B-4EEC830D3F94 Q27485460-FD992EF5-B3E8-4F40-AD80-7ACCF7E92E60 Q27487396-A89E30A5-EBDD-4216-BC5F-2F0D685FD4C9 Q27487397-3C29FB38-A224-4E80-9F2D-78191E872130 Q27487878-ED50E07B-37AB-4F35-9E26-BF6C3EF1A173 Q27489512-6F12BCBA-F107-4D8A-A3D7-955B1C249E4B Q27489859-C67B481F-4028-4D3A-81F4-978F1B4E2F83 Q27489903-E53FCB33-D554-488A-A480-4D8B483A43BA Q33572101-F476C125-7F5A-4CDD-B53E-A84B757BAE66 Q33991980-B7BA7E22-3640-4B9D-883C-4F6941147C76 Q34130628-0D0C6DF7-85FD-4109-9E85-58E68A6223EF Q34533951-4500B5B9-E436-47F5-9F10-2A6423009A41 Q35192311-06713B92-15EC-4B1B-89D2-B2D8ADDFC258 Q36478012-F717285F-3669-4B77-87AD-7721B834ACE5 Q38327430-114A70A1-D4DA-45EE-8FBC-3910431DDC13 Q38376757-EAA3865B-5D19-4332-B5D6-908A88DD008C Q39694201-A5500E00-70F0-4D95-8D08-196035DDA5EE Q39973981-8EEC9058-4DD3-4BE8-B5ED-3D34E67AA0CD Q40529775-ECEAABF8-3E20-4189-B40C-609CF549DFE3 Q42025099-48A9A836-C915-48E9-9D1C-C479161067CE Q42181383-A60FABB0-741B-49F4-8640-5A84ACC73D0C Q42270373-565C2D61-2646-4366-8E26-104F0E486E16 Q42979735-62CF4021-D39B-4FF7-A45C-B3A6D36782A2 Q43036701-6D82D8F5-2B9A-4F3E-8F00-0D21E14AF5C8

P2860

Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5

http://www.wikidata.org/entity/Q27473038

description

2006 nî lūn-bûn

@nan

2006 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մարտին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Comparison of Conventional PCR ...... nificance for Genotypes 1 to 5

@ast

Comparison of Conventional PCR ...... nificance for Genotypes 1 to 5

@en

Comparison of Conventional PCR ...... nificance for Genotypes 1 to 5

@nl

type

label

Comparison of Conventional PCR ...... nificance for Genotypes 1 to 5

@ast

Comparison of Conventional PCR ...... nificance for Genotypes 1 to 5

@en

Comparison of Conventional PCR ...... nificance for Genotypes 1 to 5

@nl

prefLabel

Comparison of Conventional PCR ...... nificance for Genotypes 1 to 5

@ast

Comparison of Conventional PCR ...... nificance for Genotypes 1 to 5

@en

Comparison of Conventional PCR ...... nificance for Genotypes 1 to 5

@nl

P1433

Q27473038-BA6C57DA-6A5E-4FBC-9A17-B620B735FFB2

P1476

Q27473038-C3B7128B-E14B-4732-A313-1A91ADA048C6

P2093

Q27473038-3A86F206-15EA-4207-9A93-CA69CEAACAF7

Q27473038-C70E6DB3-5A9F-4F2B-B27A-87599E1505A1

Q27473038-C8C08F04-EC8B-4120-A179-9E2370411B8C

Q27473038-CDAD92F4-8404-4C6F-AE93-9570E0E5980E

Q27473038-DB219E0B-9367-4F7B-9401-DB2D070F4230

Q27473038-F3DCA34E-1822-4BA6-83C7-FDF8929C1172

P2860

Q27473038-0C42FB42-90BA-4EF6-AFA4-4EC43E8A0C5C

Q27473038-0CE946AD-38A9-442F-B2CB-651EB2AC45D2

Q27473038-13919A65-0BB0-473C-8AD9-4892348A4922

Q27473038-1BEE14FA-C6F0-426C-B92D-83B7D9701BA2

Q27473038-2643D7DA-21CF-448A-9D7C-2EBBC03DBD7B

Q27473038-2D3BE4F3-EEE4-4F12-96D8-63594E29C35A

Q27473038-373086C9-C578-47D4-8ADC-CA8FE0443FD8

Q27473038-48F97D5E-D129-41D2-83A8-9F0639EF7456

Q27473038-64295A3E-DC13-4A99-9FDE-9E06723FA841

Q27473038-6F82E930-0C02-4AED-97CB-55E0E0353B9E

P304

Q27473038-46828E88-3F7C-4BFA-9B27-0862D8E73DED

P31

Q27473038-A7FFC9F7-4BF9-4075-8D55-600D2DF621F3

P3181

Q27473038-A77CF076-C07E-48CC-A6C9-10203D9B3D8E

P356

Q27473038-C57D87AF-C088-45E8-BFF7-EFAD54EB0972

P407

Q27473038-37594B20-078D-458A-B500-FAD48C6C4DDE

P433

Q27473038-35A0F4E9-9900-4BB0-87BE-6DED654BA0BC

P478

Q27473038-FA0DF3DB-79AE-423E-8F26-A9B67D2EEE6B

P50

Q27473038-26370D17-9195-4488-A284-476F4CB53D03

Q27473038-A766B81F-827A-4ACA-913A-7348C30150AF

Q27473038-EB08AB7C-D30F-4552-9D80-5ED21AC9F418

P577

Q27473038-E499AA5E-C7AA-4A42-9A36-F3F1A6892B3E

P698

Q27473038-32C6B0BC-511E-432A-96CE-BA8E6D32C01B

P921

Q27473038-74A38E80-1D86-4BB0-A9A0-32CE87930FD8

P932

Q27473038-EA355DCE-1AC0-4C48-90DE-E877C1778855

P3181

P356

JCM.44.3.729-737.2006

P1433

Journal of Clinical Microbiology

P1476

Comparison of Conventional PCR ...... nificance for Genotypes 1 to 5

@en

P2093

Barbara C Gärtner

http://www.w3.org/2001/XMLSchema#string

Dorothea Sizmann

http://www.w3.org/2001/XMLSchema#string

Michael von Wagner

http://www.w3.org/2001/XMLSchema#string

Rainer Babiel

http://www.w3.org/2001/XMLSchema#string

Ulrike Mihm

http://www.w3.org/2001/XMLSchema#string

Wolf Peter Hofmann

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of the COBAS Hepatitis C Virus (HCV) TaqMan Analyte-Specific Reagent Assay and Comparison to the COBAS Amplicor HCV Monitor V2.0 and Versant HCV bDNA 3.0 Assays

Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay.

Comparative Evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR Version 2.0 Assays for Quantification of Hepatitis C Virus RNA in Serum

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA.

Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.

Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests

P304

729-37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2893965

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/JCM.44.3.729-737.2006

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P50

Christoph Sarrazin

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16517847

http://www.w3.org/2001/XMLSchema#string

P921

P932

1393102

http://www.w3.org/2001/XMLSchema#string